A failed primary endpoint is usually read as evidence that a drug does not work. In a meaningful number of cases, the more accurate conclusion is that the trial itself was not designed to detect the effect that was actually present in the data.
Underpowering is the most common culprit, and it is often driven by optimistic assumptions baked into the sample size calculation rather than any flaw in the underlying biology. A trial powered for an effect size larger than what the drug ultimately delivers will frequently produce a statistically non-significant result even when a genuine, clinically meaningful effect exists in the population studied.
Endpoint selection compounds this problem. A composite endpoint that dilutes a strong effect on one component with a flat effect on another can mask real efficacy, while a single, narrowly defined endpoint chosen for one presumed mechanism may miss benefit occurring through a different pathway that was not anticipated at the design stage.
Patient population heterogeneity is a related and frequently underestimated issue. Enrolling a broad, unselected population increases generalizability but can dilute an effect that is concentrated in a specific biological subgroup, a problem that only becomes visible after the fact through exploratory subgroup analyses that were not adequately powered to confirm anything definitively.
The practical lesson for trial design teams is to treat the sample size calculation and endpoint selection as decisions with real consequences beyond regulatory checkboxes, since a trial that is well executed operationally can still fail to answer its own scientific question if the underlying design assumptions were wrong from the start.
Deep Dive analysis that walks through exactly where a trial’s design assumptions diverged from what the data ultimately showed, rather than treating a missed endpoint as the end of the story, such as the coverage regularly published by The Clinical Trial Vanguard, gives sponsors and investigators a more useful postmortem than the topline result alone provides.
